What are semaglutide tablets used for — and are they right for you?

What does a semaglutide tablet actually do in your body?

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases naturally after eating, and it plays a key role in telling your brain you have had enough food, slowing the rate at which your stomach empties, and steadying blood sugar after meals. Semaglutide mimics that signal in a sustained way, which is why people taking it often find their appetite drops noticeably, portions feel more satisfying, and the urge to snack between meals quietens down.

What makes the tablet form interesting is how it gets absorbed at all. Semaglutide does not survive the digestive process on its own, so Wegovy tablets contain an absorption enhancer called SNAC that allows the medicine to cross into the bloodstream through the stomach lining. For that mechanism to work properly, the tablet must be taken first thing in the morning on an empty stomach with a small amount of plain water (around 120ml) and you need to wait at least 30 minutes before any food, drink (including coffee) or other oral medicines. Swallow it whole. The NHS semaglutide medicines page explains this routine clearly and is worth reading before you start.

There is no refrigeration required, which is one practical advantage over the injection. The tablet travels in your bag without the cold-chain demands of a pen.

Who are semaglutide tablets licensed to treat?

The MHRA approved Wegovy tablets for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related health condition. Conditions that can qualify at the lower BMI threshold include type 2 diabetes, high blood pressure, high cholesterol, and obstructive sleep apnoea, among others. Lower BMI thresholds may apply for some ethnic backgrounds under UK clinical guidance.

BMI alone does not guarantee a prescription. A prescriber looks at your full picture: your medical history, any medicines you already take, whether there are contraindications, and whether the potential benefits outweigh the risks for you specifically. Semaglutide tablets are not licensed for people under 18, and they are not recommended during pregnancy, while breastfeeding, or when actively trying to conceive.

It is also worth knowing that not all semaglutide tablets serve the same purpose. Rybelsus is also an oral semaglutide product, but it is licensed for type 2 diabetes management at lower strengths (3mg, 7mg, 14mg), not for weight loss. Wegovy tablets follow a different dosing schedule entirely: starting at 1.5mg and escalating through 4mg and 9mg to a 25mg maintenance dose, with at least a month at each level. If you have seen references to the lower strengths online and assumed they relate to weight management, they do not, that distinction matters.

What does the clinical trial evidence show about weight loss?

The pivotal evidence comes from the OASIS 4 phase 3 trial, which enrolled 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes, over 64 weeks. Participants taking oral semaglutide alongside lifestyle changes lost an average of around 13.6% of their body weight, compared with around 2.4% in the placebo group. Among those who stayed fully adherent to treatment throughout the trial, average weight loss reached approximately 16–17%, though that figure needs the context: it reflects the best-case adherent subgroup, not the trial average. The full MHRA approval announcement from 11 June 2026 sets out the evidence base and is the authoritative UK source.

For context, you can read more about how Wegovy tablets compare with the injection and what to expect from treatment on our dedicated page. If you are weighing up the tablet against other licensed options, our treatment overview covers the landscape clearly. And if cost is on your mind, our semaglutide tablet pricing page explains what a legitimate private prescription typically involves.

What side effects should you know about before asking a prescriber?

Most side effects with semaglutide tablets are gastrointestinal. Nausea, diarrhoea, constipation, indigestion and burping are the most commonly reported, and in the OASIS 4 trial around 74% of participants on oral semaglutide experienced at least one GI side effect, compared with 42% on placebo. For most people these are mild to moderate and settle within the first few weeks, particularly because the dosing schedule is designed to increase gradually. If you want a broader overview of the range of conditions and situations semaglutide tablets are used for, our dedicated page covers that in full.

There are rarer but more serious effects to be aware of. Acute pancreatitis is a known risk with GLP-1 medicines, the MHRA Yellow Card scheme is the right place to report any suspected side effect, and severe stomach pain that reaches the back, with or without vomiting, should prompt urgent medical attention rather than waiting for your next clinical review.

If semaglutide tablets sound like something you would like to explore properly, our prescribers are available for a clinical conversation. If you are still at the stage of understanding what semaglutide tablets are and how they work, our overview page is a useful place to start before booking. Equally, if you want to go deeper on how semaglutide tablets are used in practice, including dosing and timing, that detail is covered there too. That is the right first step, not a purchase decision, a medical one. Start your free consultation and a GPhC-registered prescriber will review your answers the same day.